Gearing Up for Biosimilars

Publication
Article
BioPharm InternationalBioPharm International-05-15-2017
Volume 2017 eBook
Issue 1
Pages: s22-s26

Contract manufacturers prepare for anticipated biosimilars manufacturing demands through expansion and acquisition.

Compared to traditional small-molecule generics, the R&D costs and development times for biosimilars are significantly greater. With demand for services in the biosimilars space set to soar, many contract development and manufacturing organizations are increasing their capabilities in this field.  Expansions including in-house development, partnerships and joint ventures, or bolt-on acquisitions are summarized.

 

Download BioPharm International's

2017 Outsourcing Resources eBook

.

 

 

 

 

Articles in this issue
Wellspring_225.jpg
Customer Relationship Management in Contract Manufacturing
ColdChain_225.jpg
Preparing an Approach to Cold Chain for Cell- and Tissue-Based Therapies
TechTransfer_2251495479190893.jpg
Getting Biopharmaceutical Tech Transfer Right the First Time
CMOs_225.jpg
CMOs Tackle New Challenges
Biosimilars_225.jpg
Gearing Up for Biosimilars
InsourcingOutsourcing_225.jpg
Insourcing vs Outsourcing: Choosing the Right Strategy
Operations_225.jpg
Operations and Quality Oversight of CMOs
QualityMetrics_225.jpg
Quality Metrics and CMO Agreement
Audits_225.jpg
Key Considerations in Outsourced “On-Site” Audits as Part of Supplier Qualification
Recent Videos
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Christa Myers, CRB Group; Nadiyra Walker Speight, Fujifilm Diosynth Biotechnologies
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

BioPharmaSpec Launches Three New R&D Facilities in Europe

Feliza Mirasol
November 20th 2024
Article

The new European facilities located in German, Italy, and Lithuania will specialize in drug discovery and R&D services.

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Felicity Thomas
May 25th 2023
Podcast

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Thermo Fisher Introduces New CDMO and CRO Services at CPHI Milan 2024

Patrick Lavery
October 10th 2024
Article

Thermo Fisher Scientific's launch of its Accelerator Drug Development follows expansions of sites in Cincinnati, Ohio, and Bend, Ore., earlier in 2024 to enable R&D, manufacturing, and testing.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

CPHI Annual Survey Suggests 54% of Biologics Capacity in 2028 to be Held by CMOs and Hybrid Companies

Feliza Mirasol
October 9th 2024
Article

The annual survey predicts that four of the five biggest biologics capacity holders in 2028 will comprise CMOs, which will control 45% of all CMO capacity in Asia.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Cellevate to Pre-Launch Nanofiber Microcarriers for Viral Vector Production at CPHI Milan

Feliza Mirasol
October 8th 2024
Article

Cellevate's nanofiber microcarriers are the first on the market for use in manufacturing viral vectors used in gene therapy production, according to the company.

Colored water in small glass containers on white background | Image Credit: ©Baharlou/Stock.Adobe.com

Contractors Support Material Testing

Susan Haigney
October 4th 2024
Article

Contract organizations offer assistance for testing raw materials obtained from outside suppliers.

© 2024 MJH Life Sciences

All rights reserved.